(NASDAQ: UPB) Upstream Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.42%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.25%.
Upstream Bio's earnings in 2025 is -$110,059,000.On average, 4 Wall Street analysts forecast UPB's earnings for 2025 to be -$150,272,528, with the lowest UPB earnings forecast at -$155,259,150, and the highest UPB earnings forecast at -$140,164,510. On average, 4 Wall Street analysts forecast UPB's earnings for 2026 to be -$160,380,545, with the lowest UPB earnings forecast at -$185,987,523, and the highest UPB earnings forecast at -$143,938,170.
In 2027, UPB is forecast to generate -$148,250,924 in earnings, with the lowest earnings forecast at -$168,736,507 and the highest earnings forecast at -$127,226,248.